Optum Life Sciences connects data, ideas, and the life sciences industry to the rest of the health care ecosystem to catalyze innovation and impact. Optum experts help pharmaceutical manufacturers to generate evidence using real-world data (RWD), elevate value stories by addressing the needs of cross-industry stakeholders, and accelerate clinical development by collaborating across health care sectors. Life sciences leaders trust Optum RWD and domain experts to connect the dots in ways that answer tough questions, illuminate new possibilities and improve patients’ lives. Within Optum Life Sciences, the Clinical Trial Solutions business brings technology and expertise to help life sciences companies accelerate clinical development.

What was once an altruistic option is becoming a regulatory mandate. With the FDA’s recent guidance on Diversity Action Plans for clinical trials, we’ve entered a new era for clinical research that aims to increase representativeness across race, ethnicity, sex, age and other groups. To get there, trial sponsors will need to rely on real-world data more than ever before.

Tracy Ohrt, Director of Clinical Operations at Optum Life Sciences, Jenny Higley, MS, Director, Head of Feasibility CoE, Biogen, will discuss the ways real-world data can help sponsors embrace the challenge and improve both access and outcomes. By designing better studies and matching the right individuals to trial opportunities, sponsors can increase participation, diversity, and representation, and ultimately bring better care to populations that need it.

Please also check out DIA’s 2025 Global Annual Meeting taking place June 15-19, 2025! Click here